Therapeutic Asset Ratings

91,564 assets · 7,904 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Kenacort Radiculopathy	University of Miami	P4	BBB (74)
Lacosamide Epilepsy	Second Affiliated Hospital of Guangzhou Medical University	P4	BBB (74)
Lactulose Hepatic Encephalopathy	General Hospital of Shenyang Military Region	P4	BBB (74)
Lamivudine HIV Infectious Disease	José Antonio Mata Marín	P4	BBB (74)
Lamotrigine Epilepsy	Assiut University	P4	BBB (74)
Letrozole Invasive Breast Carcinoma	Emory University	P4	BBB (74)
Leuporelin Prostate Carcinoma	Mayo Clinic	P4	BBB (74)
Levetiracetam Epilepsy	Beijing Tiantan Hospital	P4	BBB (74)
Levodopa Parkinson Disease	McMaster University	P4	BBB (74)
Lithium, Elemental Bipolar Disorder	University of Aarhus	P4	BBB (74)
Lithium, Elemental Depressive Disorder	Rakitzi, Stavroula	P4	BBB (74)
Marcaine Migraine Disorder	Cairo University	P4	BBB (74)
Marcaine Neuralgia	Medipol University	P4	BBB (74)
Melatonin Traumatic Brain Injury	Children's National Research Institute	P4	BBB (74)
Memantine Alzheimer Disease	Carnot Laboratories	P4	BBB (74)
Metformin Diastolic Heart Failure	Sara ElAdawy	P4	BBB (74)
Metformin Female Infertility	Peking University Third Hospital	P4	BBB (74)
Metformin Metabolic Dysfunction-Associated Steatotic Liver Disease	Xiqiao Zhou	P4	BBB (74)
Metformin Polycystic Ovary Syndrome	Beni-Suef University	P4	BBB (74)
Methotrexate B-Cell Non-Hodgkin Lymphoma	Children's Cancer Group, China	P4	BBB (74)
Naltrexone Rheumatoid Arthritis	Truway Health, Inc.	P4	BBB (74)
Nepenthe Chronic Pain Syndrome	Bursa City Hospital	P4	BBB (74)
Neurotop Focal Epilepsy	Dhaka Medical College	P4	BBB (74)
Oxaliplatin Colorectal Neoplasm	Peking University Cancer Hospital & Institute	P4	BBB (74)
Oxaliplatin Metastatic Neoplasm	Ruijin Hospital	P4	BBB (74)

Showing 426 to 450 of 42,327 assets

PreviousPage 18 of 1694Next